EP-1035: Predictors of mucositis in volumetric modulated radiotherapy for oropharyngeal-oral cavity cancer  by Ricchetti, F. et al.
S500                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
disease. Using the Kaplan-Meier method, the estimated 5-
year contralateral recurrence-free survival (CRFS) was 90.7% 
for the total population and 81.3% for the N2b subgroup 
(p=0.038). There was no statistical difference in overall 
survival (OS) between the N0-2a and N2b subgroups (91.5% vs 
86.9%, p=0.654). 
 
Conclusion: In view of the high risk of a contralateral neck 
recurrence, bilateral neck radiotherapy should be considered 
for well-lateralized, T0-T2, HPV-related squamous cell 
carcinomas of the tonsil presenting with N2b disease.  
 
EP-1033  
Pattern of radiation induced thyroid changes in NPC 
patients in first 3 years post-chemoradiotherapy 
W.C.V. Wu
1Hong Kong Polytechnic University, HTI, Kowloon- Hong Kong- 
SAR, China 
1, Z. Lin2 
2Shantou University Medical College, Cancer Hospital, 
Shantou, China 
 
Purpose or Objective: Thyroid gland is often irradiated in 
radiotherapy (RT) of nasopharyngeal cancer (NPC) patients 
leading to radiation induced thyroid disorder. This study 
aimed to evaluate the pattern of thyroid gland changes in the 
first 3 years after the completion of chemoradiotherapy. 
 
Material and Methods: Adult NPC patients treated by 
concurrent chemo-RT (Cisplatin and 5 Fluorouracil) between 
2007 and 2011 were recruited. A 7-beam intensity modulated 
radiotherapy (IMRT) plan was delivered using 6 MV photons. 
70 and 66 Gy were prescribed to the PTVs of the nasopharynx 
and neck lymphatics respectively. Mean thyroid dose was 
obtained from dose volume histogram using the treatment 
planning system. Before RT, apart from planning CT, baseline 
thyroid hormone levels of each patient, comprising free T3 
(fT3), free T4 (fT4) and TSH were established by extracting 6 
ml of blood. Repeated measurements of the fT3, fT4, TSH 
and CT were taken at 3, 6, 12, 18, 24, 30 and 36 months 
after completion of RT. Readings of the 3 hormone levels and 
thyroid volume obtained from CT at each time interval were 
recorded. Trend lines of each parameter were plotted. The 
incidence of hypothyroidism was recorded based on the 
hormonal findings. The association between the mean thyroid 
dose and hypothyroidism was evaluated. 
 
Results: 21 patients (M = 13, F = 8) completed the 3-year 
follow up. The mean thyroid dose ranged from 18.3-61.5 Gy 
(average 42.8±9.6 Gy). The average volume of the thyroid 
gland decreased from 17.6 cm3 at pre-RT to 12.3 cm3 at 18 
months and remained stable afterward. The average level of 
fT4 decreased rapidly in the first 6 months, then slowed 
down and remained stable after 24 months (Fig 1). The 
average TSH level showed a significant rise between 6 to 18 
months and became steady afterward. The level of fT3 
remained constant throughout the study period. The 
incidence of hypothyroidism increased from 7.8% at 3 months 
to 34.4% at 18 months and remained relatively steady 
thereafter. Significant association was found between mean 
thyroid dose and incidence of hypothyroidism. 
 
Conclusion: Our study demonstrated that 18-24 months after 
chemoradiotherapy was a critical time interval where 1) 
shrinkage of thyroid gland was stabilized; 2) decrease of fT4 
and increase of TSH levels became steady; 3) incidence of 
hypothyroidism started to rise. All the parameters reached a 
relatively steady state after 36 months. Applying dose 
constraints to the thyroid gland in RT treatment planning was 
recommended to reduce the risk of hypothyroidism. 
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Purpose or Objective: Cancer cachexia is a paraneoplastic 
syndrome characterized by weight loss (WL) and sarcopenia. 
Aim of the study was to assess the impact of cachexia on 
head and neck changes during definitive cisplatin- image-
guided volumetric modulated arc radiation therapy (VMAT) in 
a series of locally advanced oropharyngeal cancer.  
 
Material and Methods: Volume variations of 
sternocleidomastoid muscle (SCM) were considered as 
surrogate of muscle changes related to sarcopenia. For the 
purpose of the study , two head and neck diameters, 
encompassing the cranial limits of II and III neck nodal levels 
(here defined as "head-diameter" and "neck-diameter", 
respectively), were measured. All parameters analyzed were 
defined retrospectively by means of on-board cone beam 
computed tomography (kV-CBCT) images at 1th , 8th, 15th, 
22th radiotherapy fraction (fx) and at the end of treatment. 
Cachexia was defined as WL > 5% during treatment. 
Statistical analysis was conducted correlating the parameters 
changes with three WL ranges: < 5%, 5-9% and > 10%. 
 
Results: 30 patients, underwent to definitive cisplatin-VMAT, 
were retrospectively evaluated . A total of 150 contoured 
SCMs and 300 diameters were collected. Median WL of 
patients during treatment was 6.5% (range, 0-16%). The most 
significant SCM shrinkage was recorded at 15th fx (mean 
reduction of 1.6 cc), in correlation with WL 5-9% and WL > 
10% (p 0.001). For "head-diameter" the peak reduction was 
recorded at the 15th fx (mean reduction of 8 mm), 
statistically correlated to WL > 10% (p 0.001). The peak 
reduction of "neck-diameter" was registered at the 22th fx 
(mean value of 6 mm). "Neck-diameter" gradually reduced 
until the end of treatment for WL > 5%. 
 
Conclusion: The head and neck volume changes here 
analyzed showed to be potentially related to cancer 
cachexia. Present data could provide relevant adaptive 
radiation therapy implications for further investigations. 
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Purpose or Objective: to assess predictors of mucositis in 
oropharyngeal and oral cavity cancer after definitive or 
adjuvant volumetric modulated arc radiotherapy (VMAT) +/- 
chemotherapy. 
 
Material and Methods: For the purpose of this retrospective 
analysis, inclusion criteria were: age ≥ 18 years, histologically 
proven carcinoma of the oropharynx and oral cavity, no 
dysphagia at baseline, radical and adjuvant treatment with 
VMAT (RapidArc®, Varian Medical System, Palo Alto, CA, 
USA). Fifty patients were evaluated. Statistical Analysis was 
performed for the following parameters as potential 
predictors of mucositis ≥ G2: total oral mucosa (OM) and OM 
minus target high-low radiation dose regions (PTVs), mean 
dose (Dmean) and maximum dose (Dmax), chemotherapy, 
weight loss, dysphagia. 
 
Results: mucositis ≥ G2 was related to total OM Dmean ≥ 50 
Gy (p .02, CI 95%: 0.1-1.3) and Dmax ≥ 65Gy  (p .04, CI 95%: 
0.1-1.3). At logistic regression, for Dmean ≥ 50 Gy and Dmax 
≥ 65 Gy, the risk of mucositis ≥ G2 increased around 4 times 
(p .04). Considering OM minus target PTVs, the following 
volumetric constraints were related to mucositis ≥ G2: V45Gy 
> 40 % (p .04, CI 95%: 0.9-2.3), V50Gy > 30 % (p .009, CI 95%: 
0.6-1.4), V55 Gy > 20 % (p.003, CI 95%: 0.5-1.2). At logistic 
regression, for OM minus target PTVs V45 > 40, V50 > 30 and 
V55 > 20 the risk of mucositis ≥ G2 increased around 5 times 
(p .05). A ratio between total OM and OM minus target PTVs > 
2.5 is related to G3 mucositis (p .03, CI 95%: 0.8-1.8). 
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Conclusion: new parameters were found as predictors of 
moderate-severe mucositis. 
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Purpose or Objective: Retrospective review of results of 
radiotherapy for stage T1 glottic carcinoma. 
 
Material and Methods: A retrospective review was done of 
all patients with squamous cell carcinoma of the glottis stage 
T1 treated with radiotherapy between 1960 and 2012 
inclusive. There were 995 patients identified. All patients 
were treated with wedged lateral or angled anterior oblique 
technique. The main site of relapse was local and hence the 
main end point for anaysis was local control at 5 years. 
Survival curves were calculated using Kaplan Meier method 
and log rank test used to comparer differences. 
 
Results: Overall the 5 year freedom from relapse was 88%. 
The only factor which influenced outcome was time period of 
radiotherapy with those between 1960 and 1980 had a 84% 
relapse free rate, significantly worse than the latter time 
period. Other factors examined included sex, age, substage 
T1a and T1b, grade, radiation dose, radiation field size and 
duration of radiation, and none of those factors had a 
significant effect on outcome. There were 121 relapses, most 
in the primary alone and most within the first two years.  
 
Conclusion: The overall 5 year freedom from relapse was 
88%. 
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Purpose or Objective: To correlate clinical late dysphagia 
with the dose received by the constrictor pharyngeal muscles 
in patients receiving induction chemotherapy (ICT) and 
radiochemotherapy (RT-CT) with SIB-VMAT technique. 
 
Material and Methods: Between July 2010 and January 2015, 
51 patients with locally advanced head and neck cancer 
underwent ICT and subsequent RT-CT with concurrent weekly 
Cisplatin. The superior, middle, and inferior (S, M, and I) 
pharyngeal constrictors muscles (CM) were delineated and 
the correlation between dosimetric parameters and late 
pharyngeal toxicity was analyzed. 
 
Results: 51 patients [M/F: 41/10, median age 56, range 30-
77, stage III: 10 (20%), stage IV: 41 (80 %)] were included in 
this analysis. The tumor site was: oropharynx in 21 (40%) 
patients, epipharynx in 10 (20%), oral cavity in 9 (18%), larynx 
in 5 (10%), and hypopharynx in 6 (12%). ICT in the majority of 
cases (74%), was based on Cisplatin - 5 -Fluorouracil, with the 
addition of Docetaxel in 26% of cases. The dose delivered to 
the primary tumor was 67.5 Gy (in 8 patients, 16 %) and 70.5 
Gy (in 43 patients, 84 %); 60 Gy and 55.5 Gy were delivered 
on high and low risk lymph node levels, in 30 fractions with 
SIB-VMAT (2 arcs) technique, respectively. With a median 
follow-up of 11 months (range 3-44), late G1 dysphagia was 
recorded in 6 patients (12%) and late G2 dysphagia was 
observed in 2 patients (4%) (CTC-AE v. 4.3). Other late 
toxicities are reported in the Table 1. G3-4 toxicities were 
not recorded. In DVH analysis, the median dose received by 
CM was 66.2 Gy (S: 67.4 Gy, M and I: 67.2 Gy), with V50 being 
96.9 % (S: 97.4%, M: 98.3%, and I: 95.9 %), and V60 being 
82.4% (S: 86.8%, M: 90.1 %, and I: 73.8%). The median dose 
received by the larynx was 63.5 Gy (V50: 94.1 %, and V60: 
66.2 %). No statistically significant difference between the 
group of patients with and without late dysphagia was 
observed. 
 
 
 
Conclusion: No statistically significant correlation between 
dose delivered to the constrictors muscles and late dysphagia 
was observed in this patients cohort. This result may depend 
on tolerability of the treatment and then by the small 
number of recorded adverse events. 
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Purpose or Objective: To evaluate the toxicity of intensity 
modulated radio-chemotherapy with simultaneous integrated 
boost technique (SIB) after induction chemotherapy in 
patients with locally advanced head and neck (H&N) cancer. 
 
Material and Methods: The IRMA studies are described in the 
table. Patients with stage III-IV H&N cancer, without 
progressive disease after induction chemotherapy (IC), 
underwent radio-chemotherapy with weekly Cisplatin 30 
